ABLEDOCS
6.4.2021 14:03:02 CEST | Business Wire | Pressemeddelelse
AbleDocs Inc. , globalt førende udbyder af tilgængelige PDF-produkter og -services, og Diversa Docs ApS , anerkendte eksperter inden for PDF- og Web-tilgængelighedsydelser, annoncerer, at de går sammen for at blive førende i Skandinavien inden for PDF-tilgængelighedsprodukter og -services.
Med en allerede mangeårig historik for samarbejde glæder begge virksomheders grundlæggere og lederteam til at udnytte hinandens muligheder for at tilbyde større fordele til eksisterende og nye kunder.
”Diversa Docs er bredt anerkendt for deres ekspertise inden for levering af PDF/UA-kompatible og tilgængelige PDF-filer, og denne erhvervelse giver vores kombinerede kundebase mulighed for at drage fordel af oplevelsen og omfanget af vores produkter og tjenester i hele Skandinavien,” siger AbleDocs 'Præsident (GLOBAL), Adam Spencer .
”Med deres fantastiske hold og fokuserede tilgang på slutbrugeren er de den ideelle partner for AbleDocs. Med vores samlede indsats kan sammen vi drive udbredelsen af næste generations PDF-tilgængelighedstjenester og -løsninger, ”siger Vice President (SCANDINAVIA), Jens Bjerre Kirkegaard .
”Tilgængelighed har altid appelleret til mig, fordi det kombinerer et teknisk felt med et humanistisk område,” siger administrerende direktør for Diversa Docs, Asbjørn Fangel-Hansen . ”Efter at have arbejdet i 12 år i den danske offentlige sektor inden for tilgængelighed og senest som ejer af en af de førende virksomheder inden for tilgængelighed i Danmark, er jeg meget beæret over at blive en del af en af de absolut førende globale aktører, når det kommer til tilgængelige dokumenter, ”tilføjer Fangel-Hansen.
Kombinationen af AbleDocs og Diversa Docs vil udvide den globale tilstedeværelse af AbleDocs med produkter, services, udvikling af løsninger og uddannelse tilpasset til lokale forhold på 49 sprog for at sikre, at kunderne får de bedst mulige tilbud.
Om Diversa Docs
Diversa Docs ApS blev grundlagt af Lars Holm-Sørensen og Asbjørn Fangel-Hansen i 2019 som søsterselskab til Diversa ApS. Siden da har virksomheden udviklet sig til at være en af de førende i Danmark med hensyn til dokumenttilgængelighed og området generelt.
Om AbleDocs Inc.
AbleDocs blev grundlagt i 2019 som et konglomerat af udbydere af PDF-tilgængelighedstjenester og er vokset til at have aktiviteter i Canada, Danmark, Tyskland, Schweiz og USA. Grundlæggerne har mere end 150 års kombineret erfaring med tilgængelige dokumenter i og har siden udvidet sine tilbud til også at inkludere en helt ny tilgang til dokumenttilgængelighedsstrategier og løsninger til tilgængelige dokument produceret i store mængder samt test af tilgængelige dokumenter.
AbleDocs er det eneste firma i verden, der garanterer, at hver fil, de producerer, overholder gældende lovgivning for tilgængelighed og bakker det op med en garanti på $ 10.000.000.
Aktuelle produkter og services fra AbleDocs inkluderer ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord og axesPDF.
For mere information, besøg https://www.abledocs.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210406005231/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum